Surgical treatment of liver metastases

Aaron R. Sasson, Elin R. Sigurdson

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Approximately 50% to 60% of patients with colorectal cancer will develop hepatic metastases during the course of their illness, with 20% to 30% of patients having liver metastases at time of diagnosis. In nearly a quarter of these patients the liver is the only site of disease. Surgical resection of isolated hepatic metastases has been associated with a 27% to 37% 5-year survival and confers a survival advantage compared to patients not undergoing resection. Thorough preoperative and intraoperative evaluation is necessary to select appropriate surgical candidates who may benefit from resection. This article examines criteria useful in patient selection, and also reviews the management of recurrent hepatic metastases and the role of repeat hepatic resection.

Original languageEnglish (US)
Pages (from-to)107-118
Number of pages12
JournalSeminars in Oncology
Volume29
Issue number2
DOIs
StatePublished - Jan 1 2002

Fingerprint

Neoplasm Metastasis
Liver
Therapeutics
Survival
Patient Selection
Colorectal Neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Surgical treatment of liver metastases. / Sasson, Aaron R.; Sigurdson, Elin R.

In: Seminars in Oncology, Vol. 29, No. 2, 01.01.2002, p. 107-118.

Research output: Contribution to journalArticle

Sasson, AR & Sigurdson, ER 2002, 'Surgical treatment of liver metastases', Seminars in Oncology, vol. 29, no. 2, pp. 107-118. https://doi.org/10.1053/sonc.2002.31676
Sasson, Aaron R. ; Sigurdson, Elin R. / Surgical treatment of liver metastases. In: Seminars in Oncology. 2002 ; Vol. 29, No. 2. pp. 107-118.
@article{85715b394416409dae8ce7663a01aac9,
title = "Surgical treatment of liver metastases",
abstract = "Approximately 50{\%} to 60{\%} of patients with colorectal cancer will develop hepatic metastases during the course of their illness, with 20{\%} to 30{\%} of patients having liver metastases at time of diagnosis. In nearly a quarter of these patients the liver is the only site of disease. Surgical resection of isolated hepatic metastases has been associated with a 27{\%} to 37{\%} 5-year survival and confers a survival advantage compared to patients not undergoing resection. Thorough preoperative and intraoperative evaluation is necessary to select appropriate surgical candidates who may benefit from resection. This article examines criteria useful in patient selection, and also reviews the management of recurrent hepatic metastases and the role of repeat hepatic resection.",
author = "Sasson, {Aaron R.} and Sigurdson, {Elin R.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1053/sonc.2002.31676",
language = "English (US)",
volume = "29",
pages = "107--118",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Surgical treatment of liver metastases

AU - Sasson, Aaron R.

AU - Sigurdson, Elin R.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Approximately 50% to 60% of patients with colorectal cancer will develop hepatic metastases during the course of their illness, with 20% to 30% of patients having liver metastases at time of diagnosis. In nearly a quarter of these patients the liver is the only site of disease. Surgical resection of isolated hepatic metastases has been associated with a 27% to 37% 5-year survival and confers a survival advantage compared to patients not undergoing resection. Thorough preoperative and intraoperative evaluation is necessary to select appropriate surgical candidates who may benefit from resection. This article examines criteria useful in patient selection, and also reviews the management of recurrent hepatic metastases and the role of repeat hepatic resection.

AB - Approximately 50% to 60% of patients with colorectal cancer will develop hepatic metastases during the course of their illness, with 20% to 30% of patients having liver metastases at time of diagnosis. In nearly a quarter of these patients the liver is the only site of disease. Surgical resection of isolated hepatic metastases has been associated with a 27% to 37% 5-year survival and confers a survival advantage compared to patients not undergoing resection. Thorough preoperative and intraoperative evaluation is necessary to select appropriate surgical candidates who may benefit from resection. This article examines criteria useful in patient selection, and also reviews the management of recurrent hepatic metastases and the role of repeat hepatic resection.

UR - http://www.scopus.com/inward/record.url?scp=0036220808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036220808&partnerID=8YFLogxK

U2 - 10.1053/sonc.2002.31676

DO - 10.1053/sonc.2002.31676

M3 - Article

C2 - 11951208

AN - SCOPUS:0036220808

VL - 29

SP - 107

EP - 118

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2

ER -